In this article, we will look at the 7 Best Strong Buy European Stocks to Invest In.
European stocks are getting a closer look as investors search beyond the crowded parts of the U.S. market and start paying closer attention to regions where valuation and earnings expectations look more constructive. This is not just about geographic diversification for its own sake. It is also about whether Europe can offer a steadier mix of improving fundamentals, fiscal support, and less demanding multiples at a time when parts of the U.S. market look stretched. J.P. Morgan Asset Management says it is “positive about a broadening of global growth,” a backdrop it believes should “support equity markets outside the US.” Fidelity makes a similar point from a different angle, arguing that “The case for Europe has strengthened considerably.”
The institutional case is fairly direct. J.P. Morgan further contends “European valuations remain attractive,” which matters more now that returns are likely to depend less on multiple expansion and more on actual earnings delivery. Franklin Templeton also argues European equities appear “well positioned for 2026,” supported by “improving earnings momentum” and “supportive valuations.” Fidelity adds that European companies should not be treated as simple macro proxies, describing them instead as global businesses with “resilient balance sheets” and “proven growth profiles.” Put together, these reports are pointing to the same idea that Europe is not just cheaper than the U.S. in headline terms; it may also offer a more interesting hunting ground for selective stock picking.
Against this backdrop, the European stocks still carrying Strong Buy ratings deserve a closer look. That brings us to the 7 Best Strong Buy European Stocks to Invest In.
Our Methodology
We used the Finviz screener to identify European stocks that carry a “Strong Buy” rating from analysts. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
7. ABIVAX Société Anonyme (NASDAQ:ABVX)
On April 2, 2026, ABIVAX Société Anonyme (NASDAQ:ABVX) appointed Michael Nesrallah as chief commercial officer. Michael Nesrallah will lead global commercial strategy and launch preparation for obefazimod as the company moves toward potential regulatory approval, bringing more than 20 years of biopharmaceutical experience, including prior senior leadership roles at Takeda.
On March 24, 2026, Barclays raised the price target on ABIVAX Société Anonyme to $148 from $142 and maintained an Overweight rating. Barclays said a “clean” Data and Safety Monitoring Board review supports continued ABTECT maintenance, with a readout expected in late Q2.
On March 15, 2026, Jefferies initiated coverage on ABIVAX Société Anonyme with a Buy rating and a $160 price target. Jefferies described obefazimod as a “differentiated” treatment for ulcerative colitis and said the upcoming Q2 maintenance readout appears “fairly de-risked,” while also pointing to potential in Crohn’s disease.
ABIVAX Société Anonyme develops therapeutics targeting chronic inflammatory diseases.
6. Aptiv PLC (NYSE:APTV)
On April 6, 2026, Wells Fargo lowered the price target on Aptiv PLC (NYSE:APTV) to $81 from $93 and maintained an Overweight rating. Wells Fargo noted the company completed the spin-off of its Electrical Distribution Systems business into Versigent and said the remaining Aptiv is now focused on higher growth products, with expectations for mid-single-digit growth over market in the next five years, which could support value realization based on updated sum-of-the-parts valuations.
On April 2, 2026, TD Cowen analyst Itay Michaeli lowered the price target on Aptiv PLC to $93 from $108 and maintained a Buy rating following the spin-off. Itay Michaeli said the valuation is based on 10x 2026E EV/EBITDA and 15x P/E, reflecting adjustments from prior assumptions.
Last month, Aptiv PLC announced details of the spin-off of its Electrical Distribution Systems business into Versigent, with a record date of March 17, 2026, and distribution before market open on April 1, 2026. Shareholders received one Versigent share for every three Aptiv shares, with cash issued in lieu of fractional shares.
Aptiv PLC provides hardware and software solutions for automotive and industrial applications.
5. AC Immune SA (NASDAQ:ACIU)
On April 7, 2026, Leerink analyst Marc Goodman said AC Immune SA (NASDAQ:ACIU) amending its collaboration with Eli Lilly for the Morphomer Tau program is “great news,” highlighting continued interest in targeting intracellular Tau for early Alzheimer’s prevention. Marc Goodman added the update suggests Eli Lilly remains committed to this approach despite prior setbacks and reflects ongoing interest in non-antibody modalities for targeting Tau.
Earlier that day, AC Immune announced an amendment to its 2018 license and collaboration agreement with Eli Lilly to continue research and development of Tau aggregation inhibitor small molecules. The amendment includes work on new Morphomer Tau candidates and back-up compounds, with AC Immune set to receive a CHF 10M upfront payment and a milestone tied to Phase 1 dosing, along with eligibility for over CHF1.7B in development, regulatory, and commercial milestones and low double-digit royalties.
On March 19, 2026, AC Immune presented Phase 1 data on its PET tracer ACI-19626, including the first in vivo imaging of TDP-43 pathology in the human brain. The company said the data support the tracer’s ability to detect pathological TDP-43 in patients, with higher uptake observed in key brain regions in patients with frontotemporal dementia compared to healthy subjects, alongside favorable safety, tolerability, and pharmacokinetic characteristics.
AC Immune SA develops therapeutic and diagnostic products targeting neurodegenerative diseases associated with protein misfolding.
4. AgomAb Therapeutics NV (NASDAQ:AGMB)
On March 26, 2026, AgomAb Therapeutics NV (NASDAQ:AGMB) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,577,230 covering the composition of matter for AGMB-447. The company said AGMB-447 is an investigational inhaled, lung-restricted small molecule inhibitor of ALK5 currently in a Phase 1b study for idiopathic pulmonary fibrosis, with the patent providing protection in the U.S. through at least 2041, excluding potential extensions.
Earlier in March, Leerink analyst Thomas J. Smith initiated coverage on Agomab with an Outperform rating and a $36 price target. The analyst cited upcoming data readouts, increasing interest in anti-fibrotic and inflammatory bowel disease treatments, and sufficient capital to reach key milestones, describing 2026 as a milestone-rich year with potential upside.
Similarly, JPMorgan initiated coverage on Agomab with an Overweight rating and a $32 price target. JPMorgan highlighted ontunisertib, an oral gut-restricted ALK5 inhibitor targeting fibrostenosing Crohn’s disease, noting Phase 2a data showed “encouraging” efficacy signals across multiple endpoints along with a clean safety profile.
AgomAb Therapeutics NV develops therapies targeting immunology and chronic fibrotic diseases.
3. SEALSQ Corp (NASDAQ:LAES)
On April 8, 2026, SEALSQ Corp (NASDAQ:LAES) said Q1 revenue is approximately $4.1M, up over 200% from $1.3M in Q1 2025, citing scaled production, progress in post-quantum innovation, expanding partnerships, and growth in its pipeline. The company said it ended the quarter with “clear commercial momentum” and reaffirmed its FY26 guidance for revenue growth of 50% to 100% year over year.
On April 2, 2026, SEALSQ and its subsidiary IC’Alps announced progress in their Common Criteria certification programs, including successful hardware security testing for the QS7001 Secure Element and renewal of IC’Alps’ site certification. The company said testing confirmed the platform passed fault injection and side-channel resistance assessments, validating its ability to withstand advanced attack scenarios, while the certification renewal supports its secure design capabilities.
On the same day, Cantor Fitzgerald lowered the price target on SEALSQ to $4 from $7 and maintained an Overweight rating. Cantor Fitzgerald cited a lower valuation multiple reflecting higher cash burn, dilution risk, and slower adoption of post-quantum security, while noting long-term demand potential as adoption develops.
SEALSQ Corp designs and markets semiconductor solutions across multiple global markets.
2. Ascendis Pharma A/S (NASDAQ:ASND)
On April 8, 2026, Ascendis Pharma A/S (NASDAQ:ASND) announced plans to list its ordinary shares directly on The Nasdaq Global Select Market, effective at the opening of trading on April 20. As part of the transition, all outstanding ADSs will be exchanged on a one-for-one basis for ordinary shares, which will continue trading under the ticker “ASND.”
Also on April 8, Ascendis Pharma reported new Week 52 data from the Phase 2 COACH trial evaluating combination therapy with once-weekly TransCon CNP and TransCon hGH in children with achondroplasia. The company said the data showed improvements beyond linear growth, including increases in arm span, spinal canal dimensions, and lower limb alignment. Mean changes in arm span Z-scores were +1.02 for treatment-naive patients and +0.66 for previously treated patients, with absolute gains of 9.4 cm and 7.9 cm, respectively. The company also reported improvements in interpedicular distance and tibial femoral angle, indicating potential benefits in reducing nerve compression and improving leg alignment, with all patients completing 52 weeks and remaining on therapy.
On April 7, 2026, Ascendis Pharma announced that Yuviwel, its TransCon CNP therapy, was granted orphan drug exclusivity by the FDA and is now commercially available in the United States.
Ascendis Pharma A/S develops TransCon-based therapies for unmet medical needs.
1. Marex Group plc (NASDAQ:MRX)
On April 8, 2026, Keefe Bruyette resumed coverage on Marex Group plc (NASDAQ:MRX) with an Outperform rating and a $60 price target. The firm named Marex among its top picks across exchanges and broker names, noting AI-related concerns and geopolitical pressures have weighed on the group, while also creating opportunities. Keefe Bruyette said the stocks are “near pivot points” and sees wealth and exchanges as preferred sub-sectors.
On April 2, 2026, UBS raised its price target on Marex Group to $60 from $56 and maintained a Buy rating. UBS said meetings with CEO Ian Lowitt pointed to additional growth opportunities, leading to an increase in its revenue growth outlook to 15%-20% from 10%-15%.
On March 27, 2026, Barclays raised its price target on Marex Group to $55 from $50 and maintained an Overweight rating following investor day. Barclays said management “struck a confident tone,” highlighting multiple growth opportunities and potential margin upside from AI, while noting preliminary Q1 estimates appear ahead of expectations.
On March 26, 2026, the company said it expects Q1 adjusted profit before tax of $140M-$150M, up 45%-55% year over year, citing strong performance during a period of elevated market volatility and average clearing client balances of around $16B.
Marex Group plc (NASDAQ:MRX) provides liquidity, market access, and infrastructure services across commodity and financial markets.
READ NEXT: 10 Best Stocks That Beat Earnings Estimates and 10 Best 52-Week Low NASDAQ Stocks to Buy Now.
Hedge Fund Resource Center